4.8 Article

Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow

Journal

CANCER RESEARCH
Volume 73, Issue 20, Pages 6111-6117

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-0310

Keywords

-

Categories

Funding

  1. Children's Cancer Institute Australia for Medical Research
  2. Balnaves Foundation
  3. NIH [CA49248]
  4. UTHealth Innovation for Cancer Prevention Research Postdoctoral Fellowship - CPRIT grant [RP101503]

Ask authors/readers for more resources

Although many clinicians and researchers work to understand cancer, there has been limited success to effectively combine forces and collaborate over time, distance, data, and budget constraints. Here we present a workflow template for multidisciplinary cancer therapy that was developed during the 2nd Annual Workshop on Cancer Systems Biology sponsored by Tufts University, Boston, Massachusetts, in July 2012. The template was applied to the development of a metronomic therapy backbone for neuroblastoma. Three primary groups were identified: clinicians, biologists, and quantitative scientists (mathematicians, computer scientists, and engineers). The workflow described their integrative interactions; parallel or sequential processes; data sources and computational tools at different stages as well as the iterative nature of therapeutic development from clinical observations to in vitro, in vivo, and clinical trials. We found that theoreticians in dialog with experimentalists could develop calibrated and parameterized predictive models that inform and formalize sets of testable hypotheses, thus speeding up discovery and validation while reducing laboratory resources and costs. The developed template outlines an interdisciplinary collaboration workflow designed to systematically investigate the mechanistic underpinnings of a new therapy and validate that therapy to advance development and clinical acceptance. Cancer Res; 73(20); 6111-7. (C) 2013 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemical Research Methods

Classical mathematical models for prediction of response to chemotherapy and immunotherapy

Narmin Ghaffari Laleh, Chiara Maria Lavinia Loeffler, Julia Grajekid, Katerina Stankova, Alexander T. Pearson, Hannah Sophie Muti, Christian Trautwein, Heiko Enderling, Jan Poleszczuk, Jakob Nikolas Kather

Summary: This study fitted differential equation models to tumor volume measurements of patients undergoing chemotherapy or cancer immunotherapy. The Gompertz model provided the best fit to the data and the general Bertalanffy and Gompertz models performed best in predicting treatment outcome. The study provides a benchmark for classical textbook models and state-of-the-art models of human tumor growth.

PLOS COMPUTATIONAL BIOLOGY (2022)

Article Chemistry, Medicinal

CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation

Kendall Carrasco, Camille Montersino, Carine Derviaux, Magali Saez-Ayala, Laurent Hoffer, Audrey Restouin, Remy Castellano, Justine Casassa, Philippe Roche, Eddy Pasquier, Sebastien Combes, Xavier Morelli, Yves Collette, Stephane Betzi

Summary: A BDII-selective compound was discovered through screening the Fr-PPIChem chemical library, showing low activity in cell-based assays but the ability to modulate anti-leukemic activity in combination with various drugs in a cell- and context-dependent differential manner.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Oncology

Rethinking the immunotherapy numbers game

Rebecca A. Bekker, Mohammad U. Zahid, Jennifer M. Binning, Bryan Q. Spring, Patrick Hwu, Shari Pilon-Thomas, Heiko Enderling

Summary: Immunotherapies have revolutionized oncology by delivering unprecedented response rates in the treatment of certain cancers. However, the reasons for varying responses among patients remain unclear. Understanding the tumor microenvironment and the tumor-immune ecosystem is crucial in predicting treatment outcomes. This article highlights the potential of integrated mathematical oncology approaches in conceptualizing the impact of immunotherapies on tumor response and introducing combination therapies to improve patient outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Medicine, General & Internal

Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta- adrenergic receptors in medulloblastoma

Mailys Rossi, Julie Talbot, Patricia Piris, Marion Le Grand, Marie-Pierre Montero, Melanie Matteudi, Emilie Agavnian-Couquiaud, Romain Appay, Celine Keime, Daniel Williamson, Duje Buric, Veronique Bourgarel, Laetitia Padovani, Steven C. Clifford, Olivier Ayrault, Eddy Pasquier, Nicolas Andre, Manon Carre

Summary: This study demonstrates the potential of beta-blockers as enhancers of radiotherapy in medulloblastoma, which may improve the treatment and quality of life of children with high-risk brain tumors.

EBIOMEDICINE (2022)

Article Oncology

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Evangeline R. Jackson, Ryan J. Duchatel, Dilana E. Staudt, Mika L. Persson, Abdul Mannan, Sridevi Yadavilli, Sarah Parackal, Shaye Game, Wai Chin Chong, W. Samantha N. Jayasekara, Marion Le Grand, Padraic S. Kearney, Alicia M. Douglas, Izac J. Findlay, Zacary P. Germon, Holly P. McEwen, Tyrone S. Beitaki, Adjanie Patabendige, David A. Skerrett-Byrne, Brett Nixon, Nathan D. Smith, Bryan Day, Neevika Manoharan, Sumanth Nagabushan, Jordan R. Hansford, Dinisha Govender, Geoff B. McCowage, Ron Firestein, Meegan Howlett, Raelene Endersby, Nicholas G. Gottardo, Frank Alvaro, Sebastian M. Waszak, Martin R. Larsen, Yolanda Colino-Sanguino, Fatima Valdes-Mora, Andria Rakotomalala, Samuel Meignan, Eddy Pasquier, Nicolas Andre, Esther Hulleman, David D. Eisenstat, Nicholas A. Vitanza, Javad Nazarian, Carl Koschmann, Sabine Mueller, Jason E. Cain, Matthew D. Dun

Summary: Diffuse midline gliomas are highly lethal childhood cancers. Palliative radiotherapy is the only established treatment with limited survival benefits. ONC201, a combination of a DRD2 antagonist and ClpP agonist, has shown promising preclinical and emerging clinical efficacy in treating diffuse intrinsic pontine gliomas. Further research is needed to understand the mechanisms of response, the impact of recurring genomic features, and the potential combination therapy with a brain penetrant PI3K/Akt inhibitor, paxalisib.

CANCER RESEARCH (2023)

Article Oncology

Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary?

Isha Harshe, Heiko Enderling, Renee Brady-Nicholls

Summary: Accurately predicting tumor growth is crucial for effective treatment. This study investigated the number of volume measurements needed to predict breast tumor growth dynamics. By calibrating the model using data from 18 untreated breast cancer patients, it was determined that the number of measurements required depended on the noise level and acceptable error of model parameters. This research provides a metric for clinicians to confidently predict patient-specific tumor growth dynamics and make informed treatment decisions.

CANCERS (2023)

Article Pharmacology & Pharmacy

Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation

Aswin Anand Pai, Ezhilpavai Mohanan, John C. Panetta, Uday P. Kulkarni, Raveen Stephen Stallon Illangeswaran, Balaji Balakrishnan, Agila Jayaraman, Eunice S. Edison, Kavitha M. Lakshmi, Anup J. Devasia, Nambiathayil Aboobacker Fouzia, Anu Korula, Aby Abraham, Biju George, Alok Srivastava, Vikram Mathews, Joseph F. Standing, Poonkuzhali Balasubramanian

Summary: A new chemotherapy regimen has significantly improved hematopoietic stem cell transplantation outcomes for patients with high-risk beta-thalassemia major, but complications still exist. A study on the dose-exposure-response relationship of treosulfan reveals that lower exposure increases the risk of graft rejection and early transplant-related mortality. Therapeutic drug monitoring-based dose adjustment may be beneficial.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Medicine, General & Internal

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

Jeremy Ariey-Bonnet, Raphael Berges, Marie-Pierre Montero, Baptiste Mouysset, Patricia Piris, Kevin Muller, Guillaume Pinna, Tim W. Failes, Greg M. Arndt, Philippe Morando, Nathalie Baeza-Kallee, Carole Colin, Olivier Chinot, Diane Braguer, Xavier Morelli, Nicolas Andre, Manon Carre, Emeline Tabouret, Dominique Figarella-Branger, Marion Le Grand, Eddy Pasquier

Summary: This study identified targetable vulnerabilities in glioblastoma using high-throughput screening, target deconvolution, and functional genomics. They validated the role of the top gene hit and discovered pharmacological synergisms through drug combination screens. The efficacy of the AURKA/BET inhibitor combination in glioblastoma was confirmed in pre-clinical models.

EBIOMEDICINE (2023)

Article Chemistry, Multidisciplinary

Conditional generation of free radicals by selective activation of alkoxyamines: towards more effective and less toxic targeting of brain tumors

Patricia Piris, Duje Buric, Toshihide Yamasaki, Paul Huchede, Mailys Rossi, Melanie Matteudi, Marie-Pierre Montero, Anne Rodallec, Romain Appay, Christine Roux, Sebastien Combes, Eddy Pasquier, Marie Castets, Nicolas Andre, Paul Bremond, Manon Carre

Summary: Brain tumors, particularly glioblastoma and medulloblastoma, are highly lethal and difficult to treat. This study presents a novel approach using alkoxyamines and a bioconjugate called ALK4-MMPp to inhibit the progression of these tumors. The compounds showed promising results in in vitro and in vivo experiments, suggesting their potential as effective anticancer drug candidates. The study also developed innovative models to monitor treatment response and demonstrated the selective targeting of tumor cells without significant damage to normal brain tissue.

CHEMICAL SCIENCE (2023)

Article Biology

Simulating tumor volume dynamics in response to radiotherapy: Implications of model selection

Nuverah Mohsin, Heiko Enderling, Renee Brady-Nicholls, Mohammad U. Zahid

Summary: Mathematical modeling is crucial in understanding radiobiology and designing treatment approaches in radiotherapy for cancer. This study compares three tumor volume dynamics models and analyzes the implications of model selection. A new metric, the point of maximum reduction of tumor volume (MRV), is introduced to quantify the impact of radiotherapy. The results emphasize the importance of caution in selecting models of response to radiotherapy due to the artifacts imposed by each model.

JOURNAL OF THEORETICAL BIOLOGY (2024)

Meeting Abstract Oncology

Engineering new cellular models to decipher H3.3K27M mutation role in DIPGs' resistance to therapies

Andria Rakotomalala, Paul Lewandowski, Quentin Bailleul, Clara Savary, Melanie Arcicasa, Christine Bal, Maud Hamadou, Paul Huchede, Audrey Restouin, Remy Castellano, Yves Collette, Audrey Vincent, Pierre-Olivier Angrand, Eric Adriaenssens, Xuefen Le Bourhis, Pierre Leblond, Marie Castets, Eddy Pasquier, Alessandro Furlan, Samuel Meignan

CANCER RESEARCH (2022)

Meeting Abstract Oncology

PHARMACO-PHOSPHO-PROTEO-GENOMICS OF PEDIATRIC HIGH-GRADE GLIOMAS - A PILOT STUDY

Izac Findlay, Dilana Staudt, Padraic Kearney, Holly McEwen, Ryan Duchatel, Evangeline Jackson, Tyrone Beitaki, Nathan Smith, Nicholas Vitanza, Ron Firestein, Jason Cain, Sabine Mueller, Eddy Pasquier, Carl Koschmann, Esther Hulleman, Javad Nazarian, Mitchell Hansen, Frank Alvaro, Melissa Davis, Sebastian Waszak, Matthew Dun

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA.

Evangeline Jackson, Ryan Duchatel, Mika Persson, Abdul Mannan, Sridevi Yadavilli, Sarah Parackal, Shaye Game, Wai Chin Chong, Samantha Jayasekara, Marion Le Grand, Padraic Kearney, Alicia Douglas, Izac Findlay, Dilana Staudt, Zacary Germon, David Skerrett-Byrne, Brett Nixon, Nathan Smith, Esther Hulleman, Bryan Day, Geoffrey McCowage, Frank Alvaro, Sebastian Waszak, Martin Larsen, Yolanda Colino-Sanguino, Fatima Valdes-Mora, Andria Rakotomalala, Samuel Meignan, Eddy Pasquier, Nicholas Vitanza, Javad Nazarian, Carl Koschmann, Jason Cain, Sabine Mueller, Matthew Dun

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

PRECLINICAL AND CASE STUDY RESULTS UNDERPINNING THE PHASE II CLINICAL TRIAL TESTING THE COMBINATION OF ONC201 AND PAXALISIB FOR THE TREATMENT OF PATIENTS WITH DIFFUSE MIDLINE GLIOMA (NCT05009992)

Matthew D. Dun, Evangeline R. Jackson, Ryan J. Duchatel, Mika L. Persson, Abdul Mannan, Sridevi Yadavilli, Sarah Parackal, Shaye Game, Wai Chin Chong, Samantha Jayasekara, Marion Le Grand, Padraic S. Kearney, Alicia M. Douglas, Izac J. Findlay, Dilana Staudt, Zacary P. Germon, David A. Skerrett-Byrne, Brett Nixon, Nathan D. Smith, Esther Hulleman, Bryan Day, Geoff B. McCowage, Frank Alvaro, Sebastian M. Waszak, Martin R. Larsen, Yolanda Colino-Sanguino, Fatima Valdes-Mora, Andria Rakotomalala, Samuel Meignan, Eddy Pasquier, Nicholas A. Vitanza, Javad Nazarian, Carl Koschmann, Jason Cain, Sabine Mueller

NEURO-ONCOLOGY (2022)

No Data Available